Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers

Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and ...
The Caledonian-Record

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis ( ...